SynthesisFrontiers in pharmacology2025
Immunomodulatory effects of ulinastatin combined with continuous blood purification in sepsis: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dose-Dependent Efficacy of Ulinastatin in Improving 28-Day and 30-Day Survival Rates in Sepsis: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Clarithromycin for treating sepsis in adults.The Cochrane database of systematic reviews · 2026Article
- Effects of meropenem plus ulinastatin on inflammatory response and complications in patients with severe septic shock.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis involves a dysregulated immune response to infection, causing inflammation and organ dysfunction. This systematic review and meta-analysis evaluated the immunomodulatory effects of ulinastatin combined with continuous blood purification (CBP) in sepsis. Methods: This study involved a literature search, data extraction, quality assessment, and meta-analysis to evaluate the effects of ulinastatin combined with CBP. A total of 34 studies, including 28 randomized controlled trials (RCTs) and 6 retrospective studies involving patients with sepsis, were included. Results: The pooled results demonstrated significant reductions in inflammatory markers including CRP (SMD: 2.210, 95% CI: 2.760 to -1.661, P < 0.0001), IL-1β (SMD: 1.536, 95% CI: 1.773 to -1.299, P < 0.0001), IL-6 (SMD: 2.679, 95% CI: 3.271 to -2.086, P < 0.0001), IL-8 (SMD: 2.959, 95% CI: 4.582 to -1.337, P < 0.0001), IL-10 (SMD: 4.449, 95% CI: 7.216 to -1.682, P = 0.002), PCT (SMD: 3.787, 95% CI: 4.597 to -2.977, P < 0.0001), TNF-α (SMD: 2.734, 95% CI: 3.480 to -1.987, P < 0.0001), and mortality (OR: 0.30, 95% CI: 0.22 to 0.42, P < 0.0001) in ulinastatin group compared with control group. Egger's test indicated significant publication bias (P = 0.002). Conclusion: Ulinastatin combined with CBP significantly reduces inflammatory markers and mortality in sepsis patients, suggesting its potential benefit in managing sepsis-related inflammation. Further studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.